Clinical Trial Update: Anti-CD20 Antibody Therapy for Sjogren's Syndrome [Phase 1]

View source ↗

Summary

Phase 1 trial update reporting the completion of a study evaluating an anti-CD20 antibody therapy for Sjogren's syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sjogren Syndrome

Drugs mentioned

• Anti-CD20 Antibody Therapy

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Sjogren's Syndrome | Phase 1 | Status: COMPLETED